SecSonar.com

UroGen Pharma Ltd. (URGN)

UroGen Pharma Ltd. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

UroGen Pharma Ltd. (URGN) is a Biotechnology company based in US with a market capitalization of $1.4B. Revenue grew 21.4% year-over-year and free cash flow was negative at -$162.7M. This page tracks URGN's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 234 employees · IPO May 4, 2017

Valuation

Valuation & price

$28.78 · as of May 17, 2026 · -24.3% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

—

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$38.02$25.76$13.49Jul 25Dec 25Jul 26Jul 7, 25$13.49Jul 9, 25$13.81Jul 11, 25$14.24Jul 15, 25$14.04Jul 17, 25$15.41Jul 21, 25$15.46Jul 23, 25$18.66Jul 25, 25$18.95Jul 29, 25$18.90Jul 31, 25$19.06Aug 4, 25$19.88Aug 6, 25$20.01Aug 11, 25$18.24Aug 13, 25$20.11Aug 15, 25$19.71Aug 19, 25$18.92Aug 21, 25$19.78Aug 25, 25$18.50Aug 27, 25$19.54Aug 29, 25$19.45Sep 3, 25$19.37Sep 5, 25$18.88Sep 9, 25$20.69Sep 11, 25$19.25Sep 16, 25$18.07Sep 18, 25$18.87Sep 22, 25$17.99Sep 24, 25$17.99Sep 26, 25$18.34Sep 30, 25$19.95Oct 2, 25$17.07Oct 6, 25$17.05Oct 8, 25$17.33Oct 10, 25$16.68Oct 14, 25$16.65Oct 16, 25$16.93Oct 21, 25$18.14Oct 23, 25$17.33Oct 27, 25$20.85Oct 29, 25$19.78Oct 31, 25$20.47Nov 4, 25$19.81Nov 6, 25$23.54Nov 10, 25$23.13Nov 12, 25$25.14Nov 14, 25$23.76Nov 18, 25$23.55Nov 20, 25$24.84Nov 25, 25$27.69Nov 28, 25$28.81Dec 2, 25$24.38Dec 4, 25$24.28Dec 8, 25$23.08Dec 10, 25$22.19Dec 12, 25$21.80Dec 16, 25$23.47Dec 18, 25$21.72Dec 22, 25$23.58Dec 24, 25$23.76Dec 29, 25$23.33Jan 2, 26$22.71Jan 6, 26$21.89Jan 8, 26$23.47Jan 12, 26$21.45Jan 14, 26$18.74Jan 16, 26$18.80Jan 21, 26$19.23Jan 23, 26$20.00Jan 27, 26$21.85Jan 29, 26$20.69Feb 2, 26$19.70Feb 4, 26$20.71Feb 9, 26$21.90Feb 11, 26$21.14Feb 13, 26$20.10Feb 18, 26$22.27Feb 20, 26$21.07Feb 24, 26$20.75Feb 26, 26$21.18Mar 2, 26$19.02Mar 4, 26$20.16Mar 6, 26$20.46Mar 10, 26$19.45Mar 12, 26$18.79Mar 17, 26$18.59Mar 19, 26$18.59Mar 23, 26$17.30Mar 25, 26$18.12Mar 27, 26$17.17Mar 31, 26$17.98Apr 2, 26$18.82Apr 7, 26$18.03Apr 9, 26$20.53Apr 13, 26$20.28Apr 15, 26$21.51Apr 17, 26$22.54Apr 22, 26$26.06Apr 24, 26$24.11Apr 28, 26$24.12Apr 30, 26$23.83May 4, 26$23.29May 6, 26$26.25May 8, 26$29.40May 12, 26$29.80May 14, 26$29.68May 18, 26$28.58May 20, 26$30.22May 22, 26$28.89May 28, 26$28.69Jun 1, 26$27.03Jun 3, 26$26.60Jun 5, 26$26.85Jun 9, 26$28.18Jun 11, 26$29.50Jun 15, 26$30.87Jun 17, 26$32.81Jun 22, 26$34.99Jun 24, 26$35.42Jun 26, 26$34.54Jul 2, 26$38.02
$13.4952-week range$38.02
Loading valuation history…

Fundamentals

Key fundamentals

$1.4B

Market cap

21.4%

Revenue growth (YoY)

88.7%

Gross margin

-$162.7M

Free cash flow (USD)

$7.9M

Net debt

12.2%

Share dilution

0/4

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$17.5MFY 2017$8.2MFY 2018$1.1MFY 2019$18.0KFY 2020$11.8MFY 2021$48.0MFY 2022$64.4MFY 2023$82.7MFY 2024$90.4MFY 2025$109.8M
$17.5M$109.8M

Free cash flow by year

2016 → 2025

FY 2016$3.5MFY 2017$-9.8MFY 2018$-37.9MFY 2019$-71.3MFY 2020$-107.1MFY 2021$-85.6MFY 2022$-87.8MFY 2023$-76.6MFY 2024$-97.1MFY 2025$-162.7M
$3.5M-$162.7M

Gross margin by year

2021 → 2025

FY 202189.3%FY 202288.1%FY 202388.7%FY 202490.2%FY 202588.7%
89.3%88.7%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 6, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventArticles of AssociationJun 23, 2026Filing
  • 8-K eventSettlement AgreementJun 2, 2026Filing
  • 8-K eventEarnings ReleaseMay 6, 2026Filing
  • Quarterly report10-Q FiledMay 6, 2026Filing

Questions

Frequently asked questions

What is UroGen Pharma Ltd.'s market cap?

UroGen Pharma Ltd. (URGN) has a market capitalization of $1.4B.

What is URGN's P/E ratio?

A meaningful P/E ratio is not available for URGN — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

Are insiders buying URGN stock?

SEC Form 4 filings show no open-market insider buys at UroGen Pharma Ltd. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

CAPR

Capricor Therapeutics, Inc.

$1.4B

SEPN

Septerna, Inc.

$1.4B

MRVI

Maravai LifeSciences Holdings, Inc.

$1.3B

PGEN

Precigen, Inc.

$1.3B

IOVA

Iovance Biotherapeutics, Inc.

$1.4B

FTRE

Fortrea Holdings Inc.

$1.5B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.